Growth Hormone-Releasing Hormone (GHRH) is a peptide research material supplied for controlled laboratory investigation of GHRH receptor activity, pituitary-derived cellular models, and growth hormone-axis signaling.
In vitro research may use GHRH to characterize ligand-receptor interactions, second-messenger activity, receptor selectivity, and other predefined molecular endpoints. References to growth hormone or endocrine signaling describe the biological pathways represented by the experimental model and do not indicate therapeutic effects or intended human outcomes.
Lot-specific analytical documentation is available through the Nordsci Certificate of Analysis Library. Researchers should review the COA associated with the applicable product lot before beginning an experiment.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Growth Hormone-Releasing Hormone (GHRH) is a peptide research material supplied for controlled laboratory investigation of GHRH receptor signaling, pituitary-derived cellular models, and defined growth hormone-axis mechanisms.
Laboratory studies may use GHRH to characterize receptor binding, receptor activation, intracellular second-messenger activity, concentration-dependent responses, and feedback-associated molecular markers. These studies are conducted under controlled experimental conditions and do not establish clinical safety, effectiveness, or suitability for human or veterinary applications.
GHRH (5mg) – Research Specifications:
| Compound | Growth Hormone-Releasing Hormone (GHRH) |
| Quantity | 5mg per vial |
| Compound Type | Synthetic peptide research material |
| Form | Lyophilized powder |
| Purity / Identity | Refer to the lot-specific Certificate of Analysis |
| Analytical Documentation | Lot-specific documentation may report HPLC, mass spectrometry, or other applicable analytical results |
| Storage Conditions | Store sealed at −20°C or below and protect from light, heat, and moisture unless otherwise stated in the applicable documentation |
| Research Classification | Laboratory research and analytical use only |
| Restrictions | Not for human or animal consumption or in vivo, diagnostic, therapeutic, food, drug, cosmetic, or dietary-supplement use |
Growth Hormone-Releasing Hormone is a naturally occurring hypothalamic signaling peptide associated with the regulation of growth hormone secretion through interactions with GHRH receptors in the anterior pituitary. Synthetic GHRH research materials allow laboratories to examine this signaling relationship under defined experimental conditions.
The GHRH receptor is a G protein-coupled receptor. In controlled cellular models, receptor engagement can be examined through binding assays, cyclic adenosine monophosphate measurements, receptor-expression analysis, and other validated molecular methods.
Laboratory investigations may also examine the relationship between GHRH-associated signaling and other components of the growth hormone axis. These studies can include measurements of receptor selectivity, intracellular signaling markers, concentration-dependent activity, or feedback-associated molecular responses.
References to pituitary signaling, growth hormone secretion, or endocrine communication identify mechanisms and experimental models. They do not indicate that GHRH changes growth hormone levels, body composition, metabolism, sleep, physical performance, recovery, or any other outcome in humans or animals.
Important Research Notice: Nordsci research materials are supplied with access to lot-specific analytical documentation. Researchers should consult the applicable Certificate of Analysis for reported identity and purity information.
THIS PRODUCT IS INTENDED EXCLUSIVELY FOR LABORATORY RESEARCH. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR IN VIVO, DIAGNOSTIC, THERAPEUTIC, FOOD, DRUG, COSMETIC, OR DIETARY-SUPPLEMENT USE.
GHRH may be evaluated in controlled cellular systems designed to represent specific components of endocrine communication. Researchers can measure receptor-associated molecular activity while controlling the cell model, exposure period, concentration range, and analytical endpoints.
Results from these experiments remain specific to the selected in vitro system. They should not be interpreted as evidence of an endocrine effect in humans or animals.
Laboratory models may use GHRH to examine molecular events associated with GHRH receptor activation and growth hormone-axis signaling. Applicable endpoints can include receptor binding, second-messenger activity, gene-expression markers, or assay-specific secretory responses.
References to growth hormone regulation describe the pathway represented by the laboratory model. They do not indicate that the product increases, restores, balances, or otherwise changes growth hormone in a human or animal subject.
GHRH-associated laboratory models may be incorporated into broader studies examining how endocrine-related molecular pathways interact within a defined cellular system. Researchers should select specific molecular markers and validated analytical methods before beginning testing.
Observed in vitro activity does not establish an effect on metabolism, energy expenditure, body weight, fat, muscle, glucose regulation, or other physiological outcomes.
Controlled laboratory systems may be used to examine molecular feedback relationships involving GHRH receptors and other growth hormone-axis components. Appropriate comparator groups can help distinguish direct receptor-associated observations from secondary assay effects.
Feedback-associated findings must be interpreted within the limitations of the selected model, controls, exposure conditions, and analytical methods.
GHRH (5mg) should be handled only by qualified laboratory personnel using established procedures for synthetic peptide research materials. Laboratories should document product receipt, lot identification, storage conditions, sample allocation, testing methods, and disposal.
No reconstitution volume, diluent selection, concentration, dosing, injection, administration, or in vivo application guidance is provided.
Protocol Design Considerations:
Note: This information is provided exclusively as a laboratory research reference. All work should be conducted by qualified personnel in appropriately equipped facilities and in accordance with applicable institutional requirements.
Lot-specific Certificates of Analysis provide analytical information associated with the applicable GHRH product lot. Documentation may include identity, purity, testing methodology, and other reported analytical results.
Researchers should confirm that the lot number on the vial corresponds with the lot number shown on the applicable COA. Analytical findings apply only to the tested lot and should not be interpreted as evidence of clinical safety, effectiveness, or approval for human or veterinary use.
Nordsci Peptides supplies GHRH (5mg) as a laboratory research material with access to lot-specific analytical documentation. Laboratories should evaluate compound identity, reported analytical results, storage requirements, batch traceability, and institutional procurement standards before use.
IMPORTANT: GHRH (5mg) is sold exclusively for laboratory research and analytical use. It is not a drug, food, dietary supplement, cosmetic, or therapeutic product. It is not approved for human or veterinary use and must not be used for consumption, diagnosis, treatment, prevention, compounding, or any in vivo procedure.
